[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513846":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":44,"responsibleParty":61,"collaborators":33,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":33,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":33,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":33,"overallStatus":47,"whyStopped":33,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Beijing Konruns Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Jincaopian Tablets group","EXPERIMENTAL","Patients receive Jincaopian Tablets 0.6g\u002Fday for 12 weeks.",[13],"Drug: Jincaopian Tablets",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Patients receive a placebo 0.6g\u002Fday for 12 weeks.",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Jincaopian Tablets","Jincaopian Tablets 0.2g tid p.o.",[9],[27],"ZY5301",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"OTHER","Placebo","Placebo 0.2g tid p.o.",[15],null,[35],{"name":36,"affiliation":37,"role":38},"Xiuxiang Teng","Beijing Hospital of Traditional Chinese Medicine","PRINCIPAL_INVESTIGATOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":33,"email":43},"CONTACT","+86 010-87906734","tengxx@126.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":53,"coordinates":54},"Point",[55,56],116.39723,39.9075,{"lat":56,"lon":55},[59,60],{"name":36,"role":41,"phone":42,"phoneExt":33,"email":43},{"name":36,"role":41,"phone":33,"phoneExt":33,"email":33},{"type":62,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100513846","phase-3-a-study-of-jincaopian-tablets-on-chronic-pelvic-pain-after-pelvic-inflammatory-disease-100513846",false,"NCT05970783","A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease","A Multicenter, Randomized, Double-blind, Dose-parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Jincaopian Tablets in Subjects with Chronic Pelvic Pain After Pelvic Inflammatory Disease","Inclusion Criteria:\n\n* Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease;\n* The average VAS score of pain in the week before enrollment is ≥4;\n* The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points);\n* Women aged 18 to 50 (including 18 and 50) with a history of sexual life;\n* Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pelvic inflammatory disease (acute attack);\n* Pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 6 months after the trial;\n* Previously diagnosed with cervical intraepithelial neoplasia, primary\u002Fsecondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases;\n* Complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis;\n* Gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms;\n* Placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages;\n* Received related treatment or took drugs with similar functions and indications within 14 days before the introduction;\n* Liver function: ALT or AST\\>1.5 times the upper limit of normal value；Renal function：Scr\\>1.0 times the upper limit of normal value;\n* Serum CA125 and erythrocyte sedimentation \\> 1.1 times the upper limit of normal value.\n* Combined with serious cardiovascular, cerebrovascular, hematopoietic system and other serious diseases;\n* Have an allergic history to the experimental drug;\n* Have a long history of alcoholism or drug abuse;\n* Intellectual disabilities or mental disorders;\n* Participated in other clinical trials within the past 3 months;\n* The investigator believes that it is not suitable to participate in this clinical trial.","FEMALE","18 Years","50 Years",{"count":74,"type":75},414,"ESTIMATED","INTERVENTIONAL",[78],"PHASE3","The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease",[81],"Chronic Pelvic Pain","2024-10-15",{"date":84,"type":85},"2024-10-17","ACTUAL",{"date":87,"type":85},"2022-11-08",{"date":89,"type":75},"2025-04",{"name":5,"class":6},1]